SNY Earnings Prediction
The chart below shows how SNY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SNY sees a +2.73% change in stock price 10 days leading up to the earnings, and a -0.04% change 10 days following the report. On the earnings day itself, the stock moves by -1.04%. This data can give you a slight idea of what to expect for the next quarter's release.
SNY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
SNY Earnings Analysis
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) Corporation (SNY.O) Earnings Conference Call
Positive
Q3 Sales Increase: The total of Q3 sales of EUR 13.4 billion, a 16% increase in CER and estimated 11% excluding the impact of phasing.
Dupixent Volume Growth: Dupixent continued to be driven by global volume growth across all indications, now reaching close to EUR 3.5 billion in the quarter.
Vaccines Business Growth: Our Vaccines business grew 26%, benefiting from an element of phasing in the flu and Beyfortus sales.
Pharmaceutical Sales Surge: Our pharmaceutical launches have been performing very well with a 67% increase in sales, resulting from strong performance across all eight medicines that we have recently launched.
Patient Impact Milestone: Dupixent delivered another quarter of strong growth, reaching the major milestone of improving the lives of more than 1 million patients currently on treatment around the world.
Negative
Q3 Sales Increase: The total of Q3 sales of EUR 13.4 billion, a 16% increase in CER and estimated 11% excluding the impact of phasing.
Dupixent Volume Growth: Dupixent continued to be driven by global volume growth across all indications, now reaching close to EUR 3.5 billion in the quarter.
Vaccines Business Growth: Our vaccines business grew 26%.
Global Beyfortus Rollout Impact: However, the global rollout of Beyfortus provided a strong contribution as well.
Pharmaceutical Sales Surge: Our pharmaceutical launches have been performing very well with a 67% increase in sales.
SNY FAQs
How does SNY typically perform around its earnings report dates?
Is Sanofi (SNY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SNY Earning Call Sentiment
Sanofi (SNY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SNY.O
1.64%Positive
The earnings call summary indicates strong financial performance with significant sales growth across various products and regions, improved gross margin, and increased business EPS. New partnerships and product launches further bolster the outlook. The Q&A section highlights confidence in future growth, particularly for Beyfortus and Dupixent. Despite some lack of clarity on share repurchases, the overall sentiment is positive, with upgraded guidance and strategic moves like the Opella acquisition. Given the strong fundamentals and optimistic guidance, the stock price is likely to experience a positive movement in the next two weeks.